Article Information
- Received July 11, 2023
- Revision received September 8, 2023
- Accepted September 19, 2023
- Published online December 8, 2023.
Author Information
- Gérard N. Bischof1,2,
- Elena Jaeger1,
- Kathrin Giehl1,2,
- Merle C. Hönig1,2,
- for the Alzheimer’s Disease Neuroimaging Initiative*,
- Peter H. Weiss3,4 and
- Alexander Drzezga1,2,5
- 1Department of Nuclear Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany
- 2Molecular Organization of the Brain, Institute for Neuroscience and Medicine II, Research Center Juelich, 52428 Juelich, Germany
- 3Cognitive Neuroscience, Institute for Neuroscience and Medicine III, Research Center Juelich, 52428 Juelich,Germany
- 4Department of Neurology, Faculty of Medicine and University Hospital of Cologne, Universityof Cologne, 50937 Cologne, Germany
- 5German Center for Neurodegenerative Diseases Bonn/Cologne, 53127 Bonn, Germany
- Correspondence should be addressed to Gérard N. Bischof at gerard.bischof{at}uk-koeln.de.
Author contributions
Author contributions: G.N.B., E.J., K.G., M.C.H., P.H.W., and A.D. designed research; G.N.B., E.J., K.G., M.C.H., P.H.W., and A.D. performed research; G.N.B., E.J., K.G., M.C.H., P.H.W., and A.D. contributed unpublished reagents/analytic tools; G.N.B., E.J., K.G., M.C.H., P.H.W., and A.D. analyzed data; G.N.B., E.J., K.G., M.C.H., P.H.W., and A.D. wrote the paper.
Disclosures
The authors declare no competing financial interests.
A.D., G.N.B., E.J., M.C.H. and P.H.W. are funded by the Deutsche Forschungsgemeinschaft—Project-ID 431549029—SFB 1451. G.N.B. received funding from Alzheimer Forschung Initiative e.V., Germany (AFI K1707). In addition, this study was supported by the German Research Foundation (DFG, DR 445/9-1). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense Award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
↵* Data used in preparation of this article were obtained from the Alzheimer’s disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). Thus, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data, but did not participate in this analysis or the writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf/.
Funding
Deutsche Forschungsgemeinschaft (DFG)
431549029 - SFB 1451; DR 445/9-1Alzheimer Forschungsinitative
AFI K1707
Other Version
- You are viewing the most recent version of this article.
- previous version (December 08, 2023).
Article usage
In this issue
